Black Diamond Therapeutics (BDTX) disclosed plans Monday to restructure business to focus on advancing its BDTX-1535 lead program candidate and extending its financial resources into Q2 2026.
Black Diamond said it expects to report initial results from phase 2 testing of BDTX-1535, a treatment for a form of recurrent non-small cell lung cancer characterized by epidermal growth factor receptor mutations, early in 2025.
The company also said chief business and financial officer Fang Ni is leaving the company as part of the restructuring, while Erika Jones, currently senior vice president of finance and principal accounting officer, was named principal financial officer.
Chief People Officer Elizabeth Montgomery is also leaving the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。